Verition Fund Management
GLUE icon

Verition Fund Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Verition Fund Management’s Portfolio GLUE Stock Details GLUE Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$496K Buy
+20,500
New +$387K ﹤0.01% 1639
2025
Q2 		– Sell
-51,725
Closed -$240K – 3721
2025
Q1 		$240K Buy
+51,725
New +$317K ﹤0.01% 2970
2023
Q4 		– Sell
-13,127
Closed -$62.9K – 2467
2023
Q3 		$62.9K Buy
+13,127
New +$84.5K ﹤0.01% 2164

Other funds holding GLUE

T. Rowe Price Associates
T. Rowe Price Associates Baltimore, Maryland $999B AUM 46.22% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
TCM
TCG Crossover Management Palo Alto, California $4.16B AUM 983.43% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.91B AUM 304.52% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $20B AUM 154.41% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
SCM
Suvretta Capital Management New York $5.47B AUM 131.34% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Verition Fund Management's GLUE Position: Q2 2026 in Review

Verition Fund Management opened a new position in Monte Rosa Therapeutics (GLUE) in Q2 2026: 20,500 shares worth $496K. The stake represents ﹤0.01% of the portfolio and ranks #1639 among its holdings. This is a return to the name: Verition Fund Management previously reported a position in GLUE as recently as Q1 2025.

Verition Fund Management first reported a position in GLUE in Q3 2023 and has held it in 3 quarters since. 192 funds tracked by Wall St. Rank hold GLUE as of Q2 2026.

  • Verition Fund Management held 20,500 shares of Monte Rosa Therapeutics worth $496K as of Q2 2026.
  • Monte Rosa Therapeutics was a new Verition Fund Management position in Q2 2026.
  • Monte Rosa Therapeutics made up ﹤0.01% of Verition Fund Management's portfolio in Q2 2026, its #1639 holding.
  • Verition Fund Management first reported a position in Monte Rosa Therapeutics in Q3 2023 and has held it in 3 quarters since.
  • 192 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2026.

Based on Verition Fund Management's 13F filing for Q2 2026, filed 14 Aug 2026.